Literature DB >> 25957352

Interactive analysis of large cancer copy number studies with Copy Number Explorer.

Scott Newman1.   

Abstract

UNLABELLED: Copy number abnormalities (CNAs) such as somatically-acquired chromosomal deletions and duplications drive the development of cancer. As individual tumor genomes can contain tens or even hundreds of large and/or focal CNAs, a major difficulty is differentiating between important, recurrent pathogenic changes and benign changes unrelated to the subject's phenotype. Here we present Copy Number Explorer, an interactive tool for mining large copy number datasets. Copy Number Explorer facilitates rapid visual and statistical identification of recurrent regions of gain or loss, identifies the genes most likely to drive CNA formation using the cghMCR method and identifies recurrently broken genes that may be disrupted or fused. The software also allows users to identify recurrent CNA regions that may be associated with differential survival.
AVAILABILITY AND IMPLEMENTATION: Copy Number Explorer is available under the GNU public license (GPL-3). Source code is available at: https://sourceforge.net/projects/copynumberexplorer/ CONTACT: scott.newman@emory.edu.
© The Author 2015. Published by Oxford University Press.

Entities:  

Mesh:

Year:  2015        PMID: 25957352      PMCID: PMC4547619          DOI: 10.1093/bioinformatics/btv298

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 Motivation

Huge volumes of genomics data from nearly every cancer type are now freely available and innovative projects such as UCSC Cancer Genomics Browser (Cline ), cBioPortal (Cerami ) and arrayMap (Cai ) have begun to collate and store this information. Those analyzing cancer copy number data often wish to know the location of recurrent CNAs in a given tumor type and which genes are likely to be driving that gain or loss. Additionally, some may wish to know which genes are recurrently broken as this can indicate a potential tumor suppressor loss or gene fusion. It is, however, challenging to analyze CNA regions in these ways using current gene-centric or non-interactive approaches. This is problematic since the presence or absence of a certain CNA can aid in diagnosis, stratify patients into different risk categories or inform therapy decisions. Copy Number Explorer rapidly generates and displays interactive CNA and breakage frequency plots from public data such as the TCGA or from the user's own study. The software requires only segmented copy number data as is generated from popular segmentation algorithms such as DNAcopy (Venkatraman and Olshen, 2007). Subsequently, it is possible to combine data from different studies or from an internal database—even if data were generated using different array designs or next generation sequencing. Here we demonstrate the utility of Copy Number Explorer by applying it to the TCGA Glioblastoma Multiforme (GBM) data (Brennan ).

2 Implementation

The software is written in R and tested using version 3.0.2. Tier 3 segmented SNP6 array copy number and survival data were downloaded from the TCGA data portal (https://tcgadata.nci.nih.gov-/tcga/). The software calculates CNA frequency of every gene in the human hg19 RefSeq gene set by assigning it the log2 ratio of the copy number segment from which it was derived. By default, any gene whose segmented log ratio is greater than 0.2 is considered gained and less than −0.2 is considered lost (thresholds are, however, customizable) and the total number of samples crossing these thresholds are calculated. Segment Gain or Loss (SGOL) scores are calculated for RefSeq genes using the SGOL function of the cghMCR package (http://bioconductor.org/packages/release-/bioc/ html/cghMCR.html). Gene-level frequency of gain, loss and breakage are calculated using Perl and R scripts. Survival analysis is performed with the R survival package according to standard methods. Interactive CNA plots and survival curves are made visible through a web browser using the Shiny R package (www.rstudio.com/shiny). An online version was deployed using ShinyApps.io (www.shinyapps.io).

3 Example

Copy Number Explorer produces frequency profiles in which recurrent CNA regions can be identified. For example, the combined profile from 580 GBM tumors showed gains of chromosome seven and losses of chromosome ten were the most common events (Fig. 1A). Numerous other focally altered (<∼10 Mb) regions were also evident including loss of 9p21.3 containing CDKN2A/B in ∼70% of samples and amplification or gain 1q32.1 containing MDM4 and PIK3C2B in ∼23% of samples. These findings are in keeping with other published studies (Brennan ).
Fig. 1.

Copy Number Explorer Workflow. (A) Aberration frequency plot shows proportion of samples with gains and losses from GBM (n = 580). Chromosomes are placed in order along the x-axis and the proportion of gains (dark grey; positive numbers) or losses (light grey; negative numbers) are shown on the y-axis. (B) cghMCR-transformed data results in a segment gain or loss (SGOL) score on the y-axis. High absolute SGOL scores indicate one or a combination of highly focal, high frequency or a high magnitude of alterations across multiple samples: SGOL score can be used to identify the gene most likely to be the target of gain or loss. Genes with the highest SGOL scores for chromosomes 1, 4, 7, 9 and 12 are indicated. (C, D) Data is partitioned based on the presence of a gain or amplification of the EGFR locus (indicated by an asterisk). Group 1 (n = 499) (C) shows 100% of cases have this abnormality whereas no cases in Group 2 (n = 81) do (D). (E) Kaplan–Meier curve shows that subjects with an EGFR gain or amplification have a poorer prognosis than those without

Copy Number Explorer Workflow. (A) Aberration frequency plot shows proportion of samples with gains and losses from GBM (n = 580). Chromosomes are placed in order along the x-axis and the proportion of gains (dark grey; positive numbers) or losses (light grey; negative numbers) are shown on the y-axis. (B) cghMCR-transformed data results in a segment gain or loss (SGOL) score on the y-axis. High absolute SGOL scores indicate one or a combination of highly focal, high frequency or a high magnitude of alterations across multiple samples: SGOL score can be used to identify the gene most likely to be the target of gain or loss. Genes with the highest SGOL scores for chromosomes 1, 4, 7, 9 and 12 are indicated. (C, D) Data is partitioned based on the presence of a gain or amplification of the EGFR locus (indicated by an asterisk). Group 1 (n = 499) (C) shows 100% of cases have this abnormality whereas no cases in Group 2 (n = 81) do (D). (E) Kaplan–Meier curve shows that subjects with an EGFR gain or amplification have a poorer prognosis than those without Several statistical frameworks aim to identify the gene targets of amplification and deletion including GISTIC, RAE and cghMCR (Aguirre ; Beroukhim ; Taylor ). Copy Number Explorer deploys cghMCR as it runs within R and does not require raw data or probe mapping information. The cghMCR transformation exacerbated known recurrent abnormalities such as amplifications of MDM4, PDGFR, EGFR, CDK4 and MDM2 and deletions of CDKN2A/B (Fig. 1B). The presence of a CNA, such as EGFR amplification in GBM, can predict outcome (Verhaak ). Copy Number Explorer can partition the data based on the presence of a gain, amplification or homozygous loss in any genomic region. If the dataset is clinically annotated, then the software can construct Kaplan–Meier curves for each group that are compared based on a log-rank test. For example, after partitioning the data based on the presence of gain or amplification of any region containing EGFR (chr7:55086725-55275031[hg19]) the gained/amplified group (n = 499) showed a poorer prognosis than the non-gained/amplified group (n = 81) (P < 0.0001 by log rank test) (Fig. 1C–E). Copy number change points often fall within genes and imply disruption due to a structural change such as an unbalanced translocation. Gene breakage can imply loss of function or alternatively gain of function through gene fusion. Copy Number Explorer produces breakpoint frequency plots summarizing the proportion of cases with copy number change points within each gene. The three most broken genes in the TCGA data were EGFR (27%), CDKN2B-AS1 (19%) and PTEN (8%; not shown). Breakage of the EGFR gene may imply an EGFR gene fusion as has been described previously while breaks in CDKN2B-AS1 and PTEN imply disruption of tumor suppressor genes either at or close to the break (Brennan ).

4 Conclusions

Copy Number Explorer is a free and easy to use tool that aids in the interpretation of copy number data from large cancer studies. We used the TCGA GBM data for this analysis, but the software can use segmented copy number data from any source, indeed the online version currently houses all publically released TCGA copy number datasets. We also note that a private instance can be run on the user's own local computer or easily be deployed online with a single R command using ShinyApps.io.
  9 in total

1.  A faster circular binary segmentation algorithm for the analysis of array CGH data.

Authors:  E S Venkatraman; Adam B Olshen
Journal:  Bioinformatics       Date:  2007-01-18       Impact factor: 6.937

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

4.  High-resolution characterization of the pancreatic adenocarcinoma genome.

Authors:  Andrew J Aguirre; Cameron Brennan; Gerald Bailey; Raktim Sinha; Bin Feng; Christopher Leo; Yunyu Zhang; Jean Zhang; Joseph D Gans; Nabeel Bardeesy; Craig Cauwels; Carlos Cordon-Cardo; Mark S Redston; Ronald A DePinho; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-15       Impact factor: 11.205

5.  Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

Authors:  Rameen Beroukhim; Gad Getz; Leia Nghiemphu; Jordi Barretina; Teli Hsueh; David Linhart; Igor Vivanco; Jeffrey C Lee; Julie H Huang; Sethu Alexander; Jinyan Du; Tweeny Kau; Roman K Thomas; Kinjal Shah; Horacio Soto; Sven Perner; John Prensner; Ralph M Debiasi; Francesca Demichelis; Charlie Hatton; Mark A Rubin; Levi A Garraway; Stan F Nelson; Linda Liau; Paul S Mischel; Tim F Cloughesy; Matthew Meyerson; Todd A Golub; Eric S Lander; Ingo K Mellinghoff; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

6.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

7.  arrayMap 2014: an updated cancer genome resource.

Authors:  Haoyang Cai; Saumya Gupta; Prisni Rath; Ni Ai; Michael Baudis
Journal:  Nucleic Acids Res       Date:  2014-11-26       Impact factor: 19.160

8.  Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser.

Authors:  Melissa S Cline; Brian Craft; Teresa Swatloski; Mary Goldman; Singer Ma; David Haussler; Jingchun Zhu
Journal:  Sci Rep       Date:  2013-10-02       Impact factor: 4.379

9.  Functional copy-number alterations in cancer.

Authors:  Barry S Taylor; Jordi Barretina; Nicholas D Socci; Penelope Decarolis; Marc Ladanyi; Matthew Meyerson; Samuel Singer; Chris Sander
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

  9 in total
  3 in total

1.  Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.

Authors:  Benjamin H Hinrichs; Scott Newman; Christina L Appin; William Dunn; Lee Cooper; Rini Pauly; Jeanne Kowalski; Michael R Rossi; Daniel J Brat
Journal:  Acta Neuropathol Commun       Date:  2016-01-13       Impact factor: 7.801

2.  Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis.

Authors:  Lindsey Lowder; Jennifer Hauenstein; Ashley Woods; Hsiao-Rong Chen; Manali Rupji; Jeanne Kowalski; Jeffrey J Olson; Debra Saxe; Matthew Schniederjan; Stewart Neill; Brent Weinberg; Soma Sengupta
Journal:  J Neurooncol       Date:  2019-05-09       Impact factor: 4.130

3.  A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells.

Authors:  Rupesh S Patel; Rodrigo Romero; Emma V Watson; Anthony C Liang; Megan Burger; Peter M K Westcott; Kim L Mercer; Roderick T Bronson; Eric C Wooten; Arjun Bhutkar; Tyler Jacks; Stephen J Elledge
Journal:  Nat Commun       Date:  2022-01-11       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.